There also have been eight new additions to the pipeline in the past month. That works out to a total of 42 VC-backed companies currently in registration to go public on U.S. exchanges, representing more than $4.6 billion in targeted raise (a net increase of just over $100m).
The full pipeline is below. We lead off with the new ones, and then proceed alphabetically:
[slideshow]
[slide title=”RealD”]
Company revenue was just over $45 million for the year ending March 27, 2009.
Shareholders include Shamrock Capital Growth Fund, with a 14.8% pre-IPO stake. www.reald.com
[slide title=”Alpha and Omega Semiconductor”]
The company plans to trade on the Nasdaq under ticker symbol AOSL, with Deutsche Bank Securities and Piper Jaffray serving as co-lead underwriters. It reports over $138 million in 2009 revenue, compared to $99 million in 2008 revenue.
Shareholders include Sequoia Capital (16.1% pre-IPO stake), Pacific Venture Partners (3.4%) and Hantech International Venture Capital (2.7%). www.aosmd.com
[slide title=”Qlik Technologies”]
Qlik reports around $157 million in 2009 revenue, compared to $118 million in 2008. Its 2009 net income was $6.86 million.
Shareholders include Accel Partners (26.7% pre-IPO stake), Jerusalem Venture Partners (25.4%) and Stiftelsen Industrifonden (10.1%). www.qlikview.com
[slide title=”Beceem Communications”]
The company reports $43 million in 2009 revenue, compared to nearly $14 million in 2008.
Beceem Communications has raised around $110 million in VC funding since 2003, from Intel Capital (20.3% pre-IPO stake), Walden International (16.3%), Global Catalyst Partners (16.3%), Khosla Ventures (5.9%), NEC, KTB Ventures, Mitsui, Motorola and Samsung. www.beceem.com
[slide title=”Energy and Power Solutions”]
The company reports around $12 million in 2009 revenue, compared to over $17 million in 2008 revenue. Shareholders include NGEN Partners, SAM Private Equity and Altira Group. www.epsway.com
[slide title=”SciQuest”]
The company reports $39 million in 2009 revenue, compared to $29 million in 2008.
SciQuest had been VC-backed before going public via a $120 million IPO in 1999. It was then taken private in 2004 by Trinity Ventures. Additional investments were made by Intersouth Partners and River Cities Capital Funds. www.sciquest.com
[slide title=”Envestnet”]
The company reports nearly $78 million in 2009 revenue, down from $92 million in 2008. It also dropped from a $5.2 million net profit in 2008 to an $872k net loss in 2009.
Envestnet has raised over $40 million in VC funding, from GRP Partners (29.14% pre-IPO stake), Foundation Capital (9.45%), Apex Venture Partners (7.2%), Edgewater Funds (7.15%) and Siguler Guff (5.24%). www.envestnet.com
[slide title=”IronPlanet”]
It plans to trade on the Nasdaq under ticker symbol IRON, with J.P. Morgan and Deutsche Bank serving as co-lead underwriters.
The company has raised nearly $47 million in VC funding, from Accel Partners (19.5% pre-IPO stake), Kleiner Perkins Caufield & Byers (19.5%), Caterpillar (9.79%), Dyncorp, Marubeni Corp., IGNITE Group and Windspeed Ventures.
[slide title=”Accretive Health”]
The company reported around $398 million in 2008 revenue, and that Oak Hill Capital Partners holds around a 21% pre-IPO ownership position. www.accretivehealth.com
[slide title=”Aldagen”]
It plans to trade on the Nasdaq, with Wells Fargo and Cowen & Co. serving as co-lead underwriters.
Aldagen has raised around $64 million in VC funding since 2000, from firms like Intersouth Partners, Harbert Venture Partners, The Aurora Funds, Tullis-Dickerson and Trelys Funds. www.aldegen.com
[slide title=”Alimera Sciences”]
It since has set its IPO terms to six million common shares being offered at between $15 and $17 per share, and would have an initial market cap of approximately $518 million, were it to price at the high end of its range.
Alimera has raised just over $71 million in VC funding since 2004, from firms like Scale Venture Partners (18.44% pre-IPO stake), Domain Associates (18.44%), Intersouth Partners (18.44%), Polaris Venture Partners (18.44%) and Venrock Associates (14.93%).
It also received a total of $16.7 million from the sale of two OTC allergy products and a lubricating eye from to Bausch & Lomb. www.alimerasciences.com
[slide title=”BG Medicine”]
BG Medicine has raised over $37 million in VC funding since 2000, from firms like Flagship Ventures (44.4% pre-IPO stake), Gilde Investment Management (14.1%) and Koniklijke Philips Electronics (5.6%). www.beyondgenomics.com
[slide title=”Broadsoft”]
The company reported $68.88 million in 2009 revenue, compared to $61.83 million in 2008. Its net loss shrunk from $11.24 million in 2008 to $7.85 million in 2009.
Broadsoft has raised around $76 million in total VC funding since 1998, from firms like Bessemer Venture Partners (23.3% pre-IPO stake), Grotech Ventures (12.6%), Charles River Ventures (12.5%), Columbia Capital (9.1%), RRE Ventures (6.7%), Crescendo Ventures and Meritech Capital Partners.
It also recently acquired Packet Island, which had raised just over $3 million from Garage Technology Ventures, Rincon Venture Partners and Startup Capital Ventures. www.broadsoft.com
[slide title=”Broadview Networks”]
Its most recent amended S-1 filing was in June 2008. It said that the company still plans to trade on the Nasdaq, with Deutsche Bank Securities and Jefferies & Co. serving as co-lead underwriters.
Last August, the company bought select assets of VC-backed Natural Convergence.
Broadview has raised nearly $300 million in total VC funding since 1997, with current shareholders including Baker Capital, MCG Capital, New Enterprise Associates, ComVentures and Lightspeed Venture Partners. www.broadviewnet.com
[slide title=”Codexis”]
It has since set its IPO terms to six million shares being offered at between $13 and $15 per share. The company would have an initial market cap of nearly $509 million, were it to price at the high end of its range.
Codexis reported product revenue of $18.55 million in 2009 revenue, up from $16.86 million in 2008.
Codexis has raised just over $80 million in VC funding since 2002, from firms like CCTV Investments, CMEA Ventures, Pequot Capital, Bio*One Capital and Pfizer. It canceled a previous $100 million IPO attempt in September 2008. www.codexis.com
[slide title=”Convio”]
The company plans to trade on the Nasdaq under ticker symbol CNVO, with Piper Jaffray and Thomas Weisel Partners serving as co-lead underwriters. It has raised over $47 million in VC funding, and lists shareholders like Granite Ventures (20.1% pre-IPO stake), Austin Ventures (15.7%), El Dorado Ventures (9.2%), Adams Street Partners (8.9%), Silverton Partners (5.2%), Pacific Partners (2.8% and Rembrandt Ventures (2.7%). www.convio.com
[slide title=”Digital Domain”]
Digital Domain plans to trade on the Nasdaq under ticker symbol DTWO, with Thomas Weisel Partners and CIBC World Markets serving as co-lead underwriters. Shareholders include Falcon Mezzanine Partners and GunnAllen Venture Partners. www.digitaldomain.com
[slide title=”Everyday Health”]
Shareholders include WF Holding Co. (29.5% pre-IPO stake), Rho Ventures (24.6%), Scale Venture Partners (7.5%), Foundation Capital (6.1%) and NeoCarta Ventures (6%).
[slide title=”EyeBlaster”]
The company first filed for a $115 million IPO in March 2008, but withdrew registration that December. It reports $65 million in 2009 revenue, compared to $63 million in 2008 and $44 million in 2007.
Eyeblaster has raised around $38 million in VC funding. Shareholders include Sycamore Technology Ventures (33.9% pre-IPO stake), Insight Venture Partners (22.6%) and Eli Barkat (managing director of BRM Capital). www.eyeblaster.com
[slide title=”Fabrinet”]
Last year, Fabrinet canceled a proposed $250 million IPO, due to “market conditions.”
Shareholders include H&Q Asia Pacific (58.3% pre-IPO stake), JDS Uniphase Corp. (6.5%) and J.F. Shea Co. (6.5%). www.fabrinet.th.com
[slide title=”Fallbrook Technologies”]
The company reports $871,000 in revenue for the nine months ending Sept. 30, 2009, compared to $1.96 million during the same period in 2008. Its income loss for the 2009 period was $11.7 million.
Fallbrook has raised around $24 million in VC funding from Robeco (24.1% pre-IPO stake) and NGEN Partners (23.7%). www.fallbrooktech.com
[slide title=”Force10 Networks”]
The company, which early last year merged with Turin Networks, reports 2009 revenue of $113 million and a net loss of $76 million.
Force10 has raised over $400 million in total VC funding since 1999, while Turin Networks had raised over $250 million. Current shareholders include Advanced Equities (28.1% pre-IPO stake), New Enterprise Associates (9.8%), DCM, U.S. Venture Partners and Meritech Capital Partners. www.force10networks.com
[slide title=”GAIN Capital Group”]
The company has raised around $172 million in VC funding, from firms like 3i Group, Cross Atlantic Capital Partners, Edison Venture Funds and VantagePoint Venture Partners. www.gaincapital.com
[slide title=”GameFly”]
The company reports around $47 million in revenue for the second and third quarters of 2009, compared to $39 million over the same period in 2008. Its operating income for the 2009 period was nearly $6 million.
GameFly has raised venture capital from Sequoia Capital (51.56% pre-IPO stake) and Tenaya Capital (5.9%). www.gamefly.com
[slide title=[“Glasshouse Technologies”]
The company reports $65 million in revenue for the first three quarters of 2009, compared to $62 million over the same period in 2008.
GlassHouse has raised over $72 million in VC funding, from firms like Sigma Partners (25.81% pre-IPO stake), GrandBanks Capital (12.49%), Kodiak Venture Partners (10.75%), Paladin Capital Group (9.3%), Jafco, Cisco Systems, Montagu Newhall Associates, Shiprock Capital and Dell Computer.
The company had filed for a $100 million IPO in 2007, but withdrew in early 2008 due to “current public market conditions.” Goldman Sachs was lead underwriter on the offering, which would have had GlassHouse listing on the Nasdaq. www.glasshousetech.com
[slide title=”JinkoSolar”]
The company raised $35 million in 2008 from CIVC, Shenzhen Capital Group Co. and Pitango Venture Capital.
[slide title=”Metropark USA”]
The company raised a small amount of expansion capital in 2007 from Claritas Capital. www.metropark.com
[slide title=”Motricity”]
The company has raised over $365 million in VC funding, from Advanced Equities (26.4% pre-IPO stake), Carl Icahn (21.12%), New Enterprise Associates (8.38%), Technology Crossover Ventures (5.54%), Massey-Burch Capital, Noro-Moseley Partners, Intel Capital, Qualcomm Ventures, Sienna Ventures, TriState Investment Group and Wakefield Group.
[slide title=”Newegg”]
The company said it had been profitable every year since 2001 and generated sales of $2.1 billion in 2008.
Insight Venture Partners holds a 12.7% pre-IPO position, based on a $20 million investment in 2005.
[slide title=”Nexsan Corp.”]
The company had planned to sell five million shares at between $10 and $12 per share, withThomas Weisel Partners serving as lead underwriter. Nexsanhas raised over $17 million in VC funding since 2003, from firms like VantagePoint Venture Partners (23.2% pre-IPO stake), GESFID (20%), RRE Ventures (6.9%) and Beechtree Capital. www.nexsan.com
[slide title=”Nexx Systems”]
It reported $22.2 million in net revenue for the first nine months of 2009.
NEXX has raised around $33 million in VC funding, from firms like Sigma Partners and Enterprise Partners Venture Capital. www.nexxsystems.com
[slide title=”Prometheus Laboratories”]
The company has raised $72.8 million in VC funding, from DLJ Merchant Banking Partners (21.4% stake), Split Rock Partners (17.4%), New Leaf Ventures (12.5%), Apax Partners (11%) , Wachovia Capital Partners (11%) and Brentwood Venture Capital (7.5%). Last April, Prometheus invested $8 million of equity into Rosetta Genomics Ltd. (Nasdaq: ROSG), as part of a licensing and collaboration agreement. www.prometheuslabs.com
[slide title=”ReachLocal”]
J.P. Morgan and BoA Merrill Lynch are serving as co-lead underwriters.
The company reported over $143 million in revenue for the first nine months of 2009, compared to around $100 million over the same period one year ago. Its net income for the 2009 period is $11.66 million, compared to a $4.47 million loss in 2008.
ReachLocal raised around $68 million in VC funding, from VantagePoint Venture Partners (53.22% pre-IPO stake), Rho Ventures (12.94%) and Galleon Group (6.76%). There is no mention of Galleon’s current troubles in the S-1 filing. www.reachlocal.com
[slide title=”Reply”]
The company reports around $34.3 million in 2009 revenue, compared to $23.33 million in 2008 revenue. Its 2009 net income was around $2.4 million, compared to a $3.3 million loss in 2008.
Reply has raised nearly $23 million in VC funding, from firms like Scale Venture Partners (21.47% pre-IPO stake), Outlook Ventures (6.47%) and ATEL Ventures. www.reply.com
[slide title=”Rules-Based Medicine”]
The company reported $14.5 million in revenue and a $911k net loss for the nine months ending 9/30/09.
Rules-Based Medicine raised a $25 million Series A round in 2007 led by Equity Group Investments, with Cross Creek Capital and Stephens Capital Partners also participating. www.rbmmaps.com
[slide title=”Solyndra”]
The company has raised over $500 million in VC funding, from firms like Argonaut Ventures (35.74%), U.S. Venture Partners (10.19%), RockPort Capital Partners (7.5%), CMEA Ventures (6.81%) and Redpoint Ventures (5.94%).
Last March, Solyndra got a $535 million loan guarantee from the Department of Energy to build a second solar panel fabrication plant in California — the first cleantech company to get such a loan. It also applied for a second loan from the DOE of $469 million, according to the S-1, and estimates that the next phase of the fab will cost $642 million.
[slide title=”SPS Commerce”]
It has since set its IPO terms to 3.33 million common shares being offered at between $11 and $13 per share. SPS would have an initial market cap of approximately $142 million, were it to price at the high end of its range.
The company raised around $71 million in VC funding, with current shareholders include Adams Street Partners, Granite Ventures, River Cities Capital Funds and Split Rock Partners. www.spscommerce.com
[slide title=”Telegent Systems”]
The company reported $111 million in revenue for the six months ending Sept. 30, with $39 million in net income.
Telegent has raised around $50 million in VC funding since 2000, from firms like New Enterprise Associates (24% pre-IPO stake), Walden International (24%), Index Ventures (12.8%) and Northern Light Venture Capital. www.telegent.com
[slide title=”TeleNav”]
The company has raised around $35 million in VC funding, from firms like Menlo Ventures (14.25% pre-IPO stake), iGlobe Partners (10.31%), Tenaya Capital and Sycamore Ventures. www.telenav.com
[slide title=”Tesla Motors”]
Tesla Motors, a San Carlos, Calif.-based maker of electric vehicles, filed for a $100 million IPO on January 30.
The company reported a $31.5 million loss for the first nine months of 2009, down from a $57.3 million loss during the same period in 2008. It said to expect continued losses until it begins making “significant” deliveries of its Model S, which is not expected until 2012.
Tesla has raised over $220 million in VC funding from firms like Draper Fisher Jurvetson, Daimler AG and VantagePoint Venture Partners.
[slide title=”Trius Therapeutics”]
The company recently set its IPO terms to six million common shares being offered at between $12 and $14 per share. It would have an initial market cap of approximately $233 million, were it to price at the high end of its offering range.
Trius has raised nearly $50 million in VC funding, from firms like Sofinnova Ventures (21.2% pre-IPO stake), Interwest Partners (17.7%), Versant Ventures (17.7%), Prism VentureWorks (13.5)%, Kleiner Perkins Caufield & Byers (11.9%) and FinTech Global Capital. www.triusrx.com
[slide title=”Vringo”]
The company reported just $36,000 in revenue for the first nine months of 2009. Shareholders include Warburg Pincus, with a 31.9% ownership stake. www.vringo.com
[/slideshow]